Skip to main content

Table 2 Detailed treatment data according to first-line chemotherapy regimen

From: Comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel including sequential treatment for metastatic pancreatic cancer: a propensity score matching approach

 

Whole study population

Matched population

FOLFIRINOX (n = 371)

Gemcitabine/nab-paclitaxel (n = 157)

P value

FOLFIRINOX (n = 151)

Gemcitabine/nab-paclitaxel (n = 151)

P value

N of cycle during first-line chemotherapy

9 (4–15)

5 (3–8)

 

9 (4–15)

5 (3–8)

Treatment duration of first-line (months)

5.6 (1.8–9.8)

4.3 (2.3–7.0)

0.03

5.9 (2.2–10.1)

4.3 (2.2–6.9)

0.01

Dose reduction during first-line chemotherapy

172 (46.4)

57 (36.3)a

0.03

76 (50.3)

52 (34.4)a

0.01

Interruptionb chemotherapy due to AEs

25 (6.8)

46 (29.3)

<  0.001

12 (7.9)

35 (23.1)

<  0.001

 Cessation treatment

21 (5.7)

24 (15.3)

 

11 (7.3)

28 (18.5)

 

 Change regimen

4 (1.1)

22 (14.0)

 

1 (0.7)

7 (4.6)

 

Best responsec

  

0.33

  

0.29

 CR

4 (1.1)

0 (0)

0.18

3 (2.0)

0 (0)

 

 PR

106 (28.9)

48 (32.4)

 

48 (32.0)

46 (32.4)

 

 SD

166 (45.2)

71 (48.0)

 

64 (42.7)

68 (47.9)

 

 PD

91 (24.8)

29 (19.6)

 

35 (23.3)

28 (19.7)

 

Response ratesc

 ORR

110 (30.0)

48 (32.4)

0.58

51 (34.0)

46 (32.4)

0.77

 DCR

276 (75.2)

119 (80.4)

0.21

115 (76.7)

114 (80.3)

0.45

Second-line treatment

245 (69.2)

92 (58.6)

0.02

103 (71.5)

88 (58.3)

0.02

 FOLFIRINOX

61

 

59

 

 Nab-paclitaxel

120

 

53

 

 Clinical trial

33

5

 

14

4

 

 Other Gemcitabined

86

0

 

34

0

 

 Other 5-FUe

6

26

 

2

25

 
  1. FFX FOLFIRINOX, GnP gemcitabine plus nab-paclitaxel, AEs adverse events, CR complete response, PR partial response, SD stable disease, PD progression of disease, ORR objective response rate, DCR disease control rate, 5-FU 5-fluorouracil, FOLFOX oxaliplatin plus 5-FU/leucovorin, FOLFIRI irinotecan plus 5-FU/leucovorin, iFAM infusional 5-FU plus doxorubicin and mitomycin-C
  2. aIncluded patients for whom nab-paclitaxel was omitted due to adverse events
  3. bDiscontinuation chemotherapy or switching of chemotherapy regimen
  4. cNot evaluated for patients with regimen change or death before response evaluation
  5. dIncluded gemcitabine single, gemcitabine plus erlotinib regimens
  6. eIncluded FL, FOLFOX, FOLFIRI, iFAM, capecitabine plus oxaliplatin, tegafur/gimestat/otastat potassium regimens